Chagas disease: Changes in knowledge and management

The Lancet Infectious Diseases

Volumn 10, Issue 8, 2010, Pages 556-570

  Lescure, François Xavier ^a   Le Loup, Guillaume ^a,d   Freilij, Hector ^e   Develoux, Michel ^a,b   Paris, Luc ^c   Brutus, Laurent ^d   Pialoux, Gilles ^a  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^e HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; NIFURTIMOX; POSACONAZOLE;

AUTOIMMUNITY; CHAGAS DISEASE; DISEASE CONTROL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TRYPANOSOMA CRUZI;

AUTOIMMUNITY; CHAGAS DISEASE; HUMANS; PROGNOSIS;

EID: 77955120400     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70098-0     Document Type: Review

References (154)

1. El-Sayed NM, Myler PJ, Bartholomeu DC The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 2005, 309:409-415.
2. Atwood JA, Weatherly DB, Minning TA, et al. The Trypanosoma cruzi proteome. Science 2005, 309:473-476.
3. WHO consultation on international biological reference preparations for Chagas diagnostic tests WHO, (accessed Nov 15, 2009). http://www.who.int/bloodproducts/ref_materials/WHO_Report_1st_Chagas_BRP_consultation_7-2007_final.pdf.
4. Moncayo A, Silveira AC Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 2009, 104(suppl 1):17-30.
5. Noireau F, Cortez MG, Monteiro FA, Jansen AM, Torrico F Can wild Triatoma infestans foci in Bolivia jeopardize Chagas disease control efforts?. Trends Parasitol 2005, 21:7-10.
6. Cecere C, Vazquez-Prokopec GM, Gürtler RE, Kitron U Reinfestation sources for Chagas disease vector, Triatoma infestans, Argentina. Emerg Infect Dis 2006, 12:1096-1102.
7. Picollo MI, Vassena C, Orihuela P Santo, et al. High resistance to pyrethroid insecticides associated with ineffective field treatments in Triatoma infestans (Hemiptera: Reduviidae) from Northern Argentina. J Med Entomol 2005, 42:637-642.
8. Chippaux JP, Postigo JR, Santalla JA, Schneider D, Brutus L Epidemiological evaluation of Chagas disease in a rural area of southern Bolivia. Trans R Soc Trop Med Hyg 2008, 102:578-584.
9. Gurtler RE, Kitron U, Cecere MC, Segura EL, Cohen JE Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina. Proc Natl Acad Sci USA 2007, 104:16194-16199.
10. Brutus L, Schneider D, Postigo J, et al. Congenital Chagas disease: diagnostic and clinical aspects in an area without vectorial transmission, Bermejo, Bolivia. Acta Trop 2008, 106:195-199.
11. Schmunis GA, Cruz JR Safety of the blood supply in Latin America. Clin Microbiol Rev 2005, 18:12-29.
12. Aguilar HM, Abad-Franch F, Dias JC, Junqueira AC, Coura JR Chagas disease in the Amazon region. Mem Inst Oswaldo Cruz 2007, 102(suppl 1):47-56.
13. Cruz-Reyes A, Pickering-Lopez JM Chagas disease in Mexico: an analysis of geographical distribution during the past 76 years-a review. Mem Inst Oswaldo Cruz 2006, 101:345-354.
14. Galavíz-Silva L, Molina-Garza DP, González-Santos MA, et al. Update on seroprevalence of anti-Trypanosoma cruzi antibodies among blood donors in northeast Mexico. Am J Trop Med Hyg 2009, 81:404-406.
15. Hernández-Becerril N, Mejía AM, Ballinas-Verdugo MA, et al. Blood transfusion and iatrogenic risks in Mexico City. Anti-Trypanosoma cruzi seroprevalence in 43 048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive. Mem Inst Oswaldo Cruz 2005, 100:111-116.
16. Attaran A Chagas' disease in Mexico. Lancet 2006, 368:1768.
17. Bowman NM, Kawai V, Levy MZ, et al. Chagas disease transmission in periurban communities of Arequipa, Peru. Clin Infect Dis 2008, 46:1822-1828.
18. Blejer JL, Saguier MC, Salamone HJ Antibodies to Trypanosoma cruzi among blood donors in Buenos Aires, Argentina. Int J Infect Dis 2001, 5:89-93.
19. Gajate P, Pietrokovsky S, Orrego L Abramo, et al. Triatoma infestans in Greater Buenos Aires, Argentina. Mem Inst Oswaldo Cruz 2001, 96:473-477.
20. Schmunis GA Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 2007, 102(suppl 1):75-85.
21. Milei J, Guerri-Guttenberg RA, Grana DR, Storino R Prognostic impact of Chagas disease in the United States. Am Heart J 2009, 157:22-29.
22. Beard CB, Pye G, Steurer FJ, et al. Chagas disease in a domestic transmission cycle, southern Texas, USA. Emerg Infect Dis 2003, 9:103-105.
23. Kjos SA, Snowden KF, Craig TM, et al. Distribution and characterization of canine Chagas disease in Texas. Vet Parasitol 2008, 152:249-256.
24. Leiby DA Blood screening and seroprevalence in the US (accessed July 6, 2010). http://www.doctorswithoutborders.org/events/symposiums/2009-dndi-treat-chagas/assets/files/DavidLeiby.pdf.
25. Kun H, Moore A, Mascola L, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009, 48:1534-1540.
26. Buekens P, Almendares O, Carlier Y, et al. Mother-to-child transmission of Chagas disease in North America: why don't we do more?. Matern Child Health J 2008, 12:283-286.
27. Steele LS, MacPherson DW, Kim J, Keystone JS, Gushulak BD The sero-prevalence of antibodies to Trypanosoma cruzi in Latin American refugees and immigrants to Canada. J Immigr Minor Health 2007, 9:43-47.
28. Muñoz J, Coll O, Juncosa T, et al. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clin Infect Dis 2009, 48:1736-1740.
29. Lescure FX, Canestri A, Melliez H, et al. Chagas disease, France. Emerg Infect Dis 2008, 14:644-646.
30. Jackson Y, Gétaz L, Wolff H, et al. Prevalence, clinical staging and risk for blood-borne transmission of Chagas disease among Latin American migrants in Geneva, Switzerland. PLoS Negl Trop Dis 2010, 4:e592.
31. Guerri-Guttenberg RA, Grana DR, Ambrosio G, Milei J Chagas cardiomyopathy: Europe is not spared!. Eur Heart J 2008, 29:2587-2591.
32. Piron M, Verges M, Munoz J, et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion 2008, 48:1862-1868.
33. El Ghouzzi MH, Boiret E, Wind F, et al. Testing blood donors for Chagas disease in the Paris area, France: first results after 18 months of screening. Transfusion 2009, published online Nov 9. 10.1111/j.1537-2995.2009.02476.x.
34. Dutra WO, Gollob KJ Current concepts in immunoregulation and pathology of human Chagas disease. Curr Opin Infect Dis 2008, 21:287-292.
35. Bonney KM, Engman DM Chagas heart disease pathogenesis: one mechanism or many?. Curr Mol Med 2008, 8:510-518.
36. Cunha-Neto E, Bilate AM, Hyland KV, et al. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 2006, 39:41-54.
37. Tarleton RL Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001, 31:550-554.
38. Higuchi MD, Ries MM, Aiello VD, et al. Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg 1997, 56:485-489.
39. Schijman AG, Vigliano CA, Viotti RJ, et al. Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic chagas heart desease. Am J Trop Med Hyg 2004, 70:210-220.
40. Miles MA, Llewellyn MS, Lewis MD, et al. The molecular epidemiology and phylogeography of Trypanosoma cruzi and parallel research on leishmania: looking back and to the future. Parasitology 2009, 136:1509-1528.
41. Gaunt MW, Yeo M, Frame IA Mechanisms of genetic exchange in American trypanosomes. Nature 2003, 421:936-939.
42. Zingales B, Andrade SG, Briones MR, et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz 2009, 104:1051-1054.
43. Sturm NR, Campbell DA Alternative lifestyles: the population structure of Trypanosoma cruzi. Acta Trop 2010, 155:35-43.
44. Burgos JM, Begher S, Silva HM, et al. Molecular identification of Trypanosoma cruzi I tropism for central nervous system in Chagas reactivation due to AIDS. Am J Trop Med Hyg 2008, 78:294-297.
45. Risso MG, Garbarino GB, Mocetti E, et al. Differential expression of a virulence factor, the trans-sialidase, by the main Trypanosoma cruzi phylogenetic lineages. J Infect Dis 2004, 189:2250-2259.
46. Bustamante JM, Bixby LM, Tarleton RL Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 2008, 14:542-550.
47. Laucella SA, Mazliah DP, Bertocchi G, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009, 49:1675-1684.
48. Cazorla SI Vaccinations appraoches againts T cruzi infection. Expert Rev Vaccines 2009, 8:921-935.
49. Tarleton RL Immune system recognition of Trypanosoma cruzi. Curr Opin Immunol 2007, 19:430-434.
50. Martin DL, Weatherly DB, Laucella SA, et al. CD8 + T-Cell responses to Trypanosoma cruzi are highly focused on strain variant trans sialidase epitopes. PloS Pathog 2006, 2:e77.
51. Ribeiro BM, Crema E, Rodrigues V Analysis of the cellular immune response in patients with the digestive and indeterminate forms of Chagas disease. Hum Immunol 2008, 69:484-489.
52. Costa GC, da Costa Rocha MO, Moreira PR, et al. Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy. J Infect Dis 2009, 199:451-454.
53. Ramasawmy R, Cunha-Neto E, Faé KC, et al. BAT1, a putative anti-inflammatory gene, is associated with chronic Chagas cardiomyopathy. J Infect Dis 2006, 193:1394-1399.
54. Cruz-Robles D, Chavez-Gonzalez JP, Cavazos-Quero MM, et al. Association between IL-1B and IL-1RN gene polymorphisms and Chagas' disease development susceptibility. Immunol Invest 2009, 38:231-239.
55. Drigo SA, Cunha-Neto E, Ianni B, et al. TNF gene polymorphisms are associated with reduced survival in severe Chagas' disease cardiomyopathy patients. Microbes Infect 2006, 8:598-603.
56. Faé KC, Drigo SA, Cunha-Neto E, et al. HLA andbeta-myosin heavy chain do not influence susceptibility to Chagas disease cardiomyopathy. Microbes Infect 2000, 2:745-751.
57. Borras S Garcia, Racca L, Cotorruelo C, et al. Distribution of HLA-DRB1 alleles in Argentinean patients with Chagas' disease cardiomyopathy. Immunol Invest 2009, 38:268-275.
58. Araújo-Jorge TC, Waghabi MC, Mde N Soeiro, et al. Pivotal role for TGF-beta in infectious heart disease: The case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy. Cytokine Growth Factor Rev 2008, 19:405-413.
59. Prata A Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001, 1:92-100.
60. Blum JA, Zellweger MJ, Burri C, Hatz C Cardiac involvement in African and American trypanosomiasis. Lancet Infect Dis 2008, 10:631-641.
61. Le Loup G, Lescure FX, Develoux M, Pialoux G Chagas disease: clinical aspects and treatment in non-endemic countries. Presse Med 2009, 38:1654-1666.
62. Viotti RJ, Vigliano C, Laucella S, et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 2004, 90:655-660.
63. Rochitte CE, Oliveira PF, Andrade JM, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol 2005, 46:1553-1558.
64. Molina RB, Matsubara BB, Hueb JC, et al. Dysautonomia and ventricular dysfunction in the indeterminate form of Chagas disease. Int J Cardiol 2006, 113:188-193.
65. Cianciulli TF, Lax JA, Saccheri MC, et al. Early detection of left ventricular diastolic dysfunction in Chagas' disease. Cardiovasc Ultrasound 2006, 4:18.
66. Pazin-Filho A, Romano MM, Almeida-Filho OC, et al. Minor segmental wall motion abnormalities detected in patients with Chagas' disease have adverse prognostic implications. Braz J Med Biol Res 2006, 39:483-487.
67. Bestetti RB, Cardinalli-Neto A Sudden cardiac death in Chagas heart disease in the contemporary era. Int J Cardiol 2008, 131:9-17.
68. Carod-Artal FJ Stroke: a neglected complication of American trypanosomiasis (Chagas' disease). Trans R Soc Trop Med Hyg 2007, 101:1075-1080.
69. Coura JR, Abreu LL, Pereira JB, Willcox HP Morbidity in Chagas' disease. IV. Longitudinal study of 10 years in Pains and Iguatama, Minas Gerais, Brazil. Mem Inst Oswaldo Cruz 1985, 80:73-80. (in Portuguese).
70. Pompilio MA, Dorval ME, Cunha RV, Britto C, Borges-Pereira J Epidemiological, clinical and parasitological aspects of Chagas' disease in Mato Grosso do Sul State. Rev Soc Bras Med Trop 2005, 38:473-478.
71. Pereira JB, da Cunha RV, Willcox HP, Coura JR Development of chronic human chagas cardiopathy in the hinterland of the Paraba State, Brazil, in a 4·5 year period. Rev Soc Bras Med Trop 1990, 23:141-147.
72. Oliveira-Filho J, Viana LC, Vieira-de-Melo RM, et al. Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas Disease cohort. Stroke 2005, 36:2015-2017.
73. Nunes MC, Barbosa MM, Ribeiro AL, Barbosa FB, Rocha MO Ischemic cerebrovascular events in patients with Chagas cardiomyopathy a prospective follow-up study. J Neurol Sci 2009, 278:96-101.
74. Salas NA, Cot M, Schneider D, et al. Risk factors and consequences of congenital Chagas disease in Yacuiba, south Bolivia. Trop Med Int Health 2007, 12:1498-1505.
75. Torrico F, Alonso-Vega C, Suarez E, et al. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg 2004, 70:201-209.
76. Hermann E, Truyens C, Alonso-Vega C, et al. Congenital transmission of Trypanosoma cruzi is associated with maternal enhanced parasitemia and decreased production of interferon-gamma in response to parasite antigens. J Infect Dis 2004, 189:1274-1281.
77. Burgos JM, Altcheh J, Bisio M, et al. Direct molecular profiling of minicircle signatures and lineages of Trypanosoma cruzi bloodstream populations causing congenital Chagas disease. Int J Parasitol 2007, 37:1319-1327.
78. Torrico F, Vega CA, Suarez E, et al. Are maternal re-infections with Trypanosoma cruzi associated with higher morbidity and mortality of congenital Chagas disease?. Trop Med Int Health 2006, 11:628-635.
79. Chippaux JP, Clavijo AN, Santalla JA, et al. Antibody drop in newborns congenitally infected by Trypanosoma cruzi treated with benznidazole. Trop Med Int Health 2010, 15:87-93.
80. Martin-Davila P, Fortun J, Lopez-Velez R, et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008, 21:60-96.
81. Campos SV, Strabelli TM, Neto V Amato, et al. Risk factors for Chagas disease reactivation after heart transplantation. J Heart Lung Transplant 2008, 27:597-602.
82. Altclas J, Sinagra A, Dictar M, et al. Chagas desease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 2005, 36:123-129.
83. Diez M, Favaloro L, Bertolotti A, et al. Usefulness of PCR strategies for early diagnosis of Chagas disease reactivation and treatment follow up in heart transplantation. Am J Transplant 2007, 7:1633-1640.
84. Cordova E, Boschi A, Ambrosioni J, et al. Reactivation of chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007. Int J Infect Dis 2008, 12:587-592.
85. Sartori AM, Neto JE, Nunes EV, et al. Trypanosoma cruzi parasitemia in chronic Chagas disease comparison between human immunodeficiency virus (HIV) positive and HIV negative patients. J Infect Dis 2002, 186:872-875.
86. Da-Cruz AM, Igrepa RP, Dantas W, et al. Long-term follow-up of co-infected HIV and Trypanosoma cruzi Brazilian patients. Trans R Soc Trop Med Hyg 2004, 98:728-733.
87. Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, et al. Chagas encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis 2009, 9:324-330.
88. Le Loup G, Ibrahim K, Malvy D Chagas disease and immunodeficiency: HIV infection and transplantation. Bull Soc Pathol Exot 2009, 102:310-318.
89. Portela-Lindoso AA, Shikanai-Yasuda MA Chronic Chagas' disease: from xenodiagnosis and hemoculture to polymerase chain reaction. Rev Saude Publica 2003, 37:107-115.
90. Ferreira AW, Belem ZR, Lemos EA, Reed SG, Campos-Neto A Enzyme-linked immunosorbent assay for serological diagnosis of Chagas' disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides. J Clin Microbiol 2001, 39:4390-4395.
91. Duarte AM, de Andrade HM, do Monte SJ, de Toledo Vde P, Guimarães TM Assessment of chemiluminescence and PCR effectiveness in relation to conventional serological tests for the diagnosis of Chagas' disease. Rev Soc Bras Med Trop 2006, 39:385-387.
92. Gadelha AA, Verçosa AF, Lorena VM, et al. Chagas' disease diagnosis: comparative analysis of recombinant ELISA with conventional ELISA and the haemagglutination test. Vox Sang 2003, 85:165-170.
93. Pirard M, Lihoshi N, Boelaert M, et al. The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion 2005, 45:554-561.
94. Malan AK, Avelar E, Litwin SE, Hill HR, Litwin CM Serological diagnosis of Trypanosoma cruzi evaluation of three enzyme immunoassays and an indirect immunofluorescent assay. J Med Microbiol 2006, 55:171-178.
95. Oelemann WM, Teixeira MD, Da Costa GC Veríssimo, et al. Evaluation of three commercial enzyme-linked immunosorbent assays for diagnosis of Chagas' disease. J Clin Microbiol 1998, 36:2423-2427.
96. Gorlin J, Rossmann S, Robertson G, et al. Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening. Transfusion 2008, 48:531-540.
97. Tobler LH, Contestable P, Pitina L, et al. Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donors. Transfusion 2007, 47:90-96.
98. Luquetti AO, Ponce C, Ponce E, et al. Chagas' disease diagnosis: a multicentric evaluation of Chagas Stat-Pak, a rapid immunochromatographic assay with recombinant proteins of Trypanosoma cruzi. Diagn Microbiol Infect Dis 2003, 46:265-271.
99. Ponce C, Ponce E, Vinelli E, et al. Validation of a rapid and reliable test for diagnosis of chagas' disease by detection of Trypanosoma cruzi-specific antibodies in blood of donors and patients in central America. J Clin Microbiol 2005, 43:5065-5068.
100. Roddy P, Goiri J, Flevaud L, et al. Field evaluation of a rapid immunochromatographic assay for detection of Trypanosoma cruzi infection by use of whole blood. J Clin Microbiol 2008, 46:2022-2027.
101. Sosa-Estani S, Gamboa-León MR, Del Cid-Lemus J, et al. Use of a rapid test on umbilical cord blood to screen for Trypanosoma cruzi infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico. Am J Trop Med Hyg 2008, 79:755-759.
102. Chippaux JP, Santalla JA, Postigo JR, et al. Sensitivity and specificity of Chagas Stat-Pak test in Bolivia. Trop Med Int Health 2009, 14:732-735.
103. Gomes ML, Galvao LM, Macedo AM, Pena SD, Chiari E Chagas disease diagnosis: comparative analysis of parasitologic, molecular, and serologic methods. Am J Trop Med Hyg 1999, 60:205-210.
104. Meira WS, Galvão LM, Gontijo ED, et al. Trypanosoma cruzi recombinant complement regulatory protein: a novel antigen for use in an enzyme-linked immunosorbent assay for diagnosis of Chagas' disease. J Clin Microbiol 2002, 40:3735-3740.
105. Castro AM, Luquetti AO, Rassi A, et al. Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi. Parasitol Res 2002, 88:894-900.
106. Galvão LM, Chiari E, Macedo AM, et al. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J Clin Microbiol 2003, 41:5066-5070.
107. Gil J, Pavía P, Montilla M, et al. Comparison of a PCR test based on the histone H2A/SIRE genes with classical serological tests for the diagnosis of chronic Chagas disease in Colombian patients. Biomedica 2007, 27(suppl 1):83-91.
108. Fitzwater S, Calderon M, Lafuente C, et al. Polymerase chain reaction for chronic Trypanosoma cruzi infection yields higher sensitivity in blood clot than buffy coat or whole blood specimens. Am J Trop Med Hyg 2008, 79:768-770.
109. Altcheh J, Corral R, Biancardi MA, Freilij H Anti-F2/3 antibodies as cure marker in children with congenital Trypanosama cruzi infection. Medicina (B Aires) 2003, 63:37-40.
110. Leiby DA, Wendel S, Takaoka DT, et al. Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits. J Clin Microbiol 2000, 38:639-642.
111. Rassi A, Rassi A, Little WC, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 2006, 355:799-808.
112. Viotti R, Vigliano C, Lococo B, et al. Clinical predictors of chronic chagasic myocarditis progression. Rev Esp Cardiol 2005, 58:1037-1044.
113. Viotti R, Vigliano C, Lococo B, et al. Exercice stress testing as a predictor of progression of early chronic Chagas heart disease. Heart 2006, 92:403-404.
114. Carrasco HA, Parada H, Guerrero L, et al. Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas' disease. Int J Cardiol 1994, 43:27-38.
115. Dias JC Pinto The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med 2006, 144:772-774.
116. Salles G, Xavier S, Sousa A, Hasslocher-Moreno A, Cardoso C Prognostic value of QT interval parameters for mortality risk stratification in Chagas' disease: results of a long-term follow-up study. Circulation 2003, 108:305-312.
117. Rassi A, Rassi A, Rassi SG Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 2007, 115:1101-1108.
118. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006, 144:724-734.
119. Marin-Neto JA, Rassi A, Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the Benznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008, 156:37-43.
120. Raney AR, Bello D Cardiovascular magnetic resonance assessment of ischemic and nonischemic cardiomyopathies. Heart Fail Clin 2006, 2:145-161.
121. Leite LR, Fenelon G, Simoes A, et al. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. J Cardiovasc Electrophysiol 2003, 14:567-573.
122. Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996, 348:1407-1413.
123. Estani S Sosa, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998, 59:526-529.
124. Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 2002, 1. CD003463.
125. Reyes PA, Vallejo M Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev 2005, 4. CD004102.
126. Pérez-Molina JA, Pérez-Ayala A, Moreno S, et al. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009, 64:1139-1147.
127. Sosa-Estani S, Segura EL Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 2006, 19:583-587.
128. Punukollu G, Gowda RM, Khan IA, Navarro VS, Vasavada BC Clinical aspects of the Chagas' heart disease. Int J Cardiol 2007, 115:279-283.
129. Acquatella H Echocardiography in Chagas heart disease. Circulation 2007, 115:1124-1131.
130. Kuschnir E, Sgammini H, Castro R, et al. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy. Arq Bras Cardiol 1985, 45:249-256.
131. Secretaria de Vigilância em Saúde. Brazilian Consensus on Chagas disease. Rev Soc Bras Med Trop 2005, 38:7-29. Ministério da Saúde.
132. Carrasco HA, Barboza JS, Inglessis G, Fuenmayor A, Molina C Left ventricularcineangiography in Chagas disease detection of early myocardial damage. Am Heart J 1982, 104:595-602.
133. Andrade AL, Martelli CM, Oliveira RM, et al. Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg 2004, 71:594-597.
134. Coura JR, de Abreu LL, Willcox HP, Petana W Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas disease, in a field area with interrupted transmission. I. Preliminary evaluation. Rev Soc Bras Med Trop 1997, 30:139-144.
135. Garcia S, Ramos CO, Senra JF, et al. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 2005, 49:1521-1528.
136. Bustamante JM, Presti MS, Rivarola HW, et al. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. Int J Antimicrob Agents 2007, 29:733-737.
137. Lauria-Pires L, Braga MS, Vexenat AC, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000, 63:111-118.
138. Braga MS, Lauria-Pires L, Arganaraz ER, Nascimento RJ, Teixeira AR Persistent infections in chronic Chagas disease patients treated with anti-trypanosoma cruzi nitroderivatives. Rev Int Med Trop Sao Paulo 2000, 42:157-161.
139. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007, 298:2171-2181.
140. Viotti R, Vigliano C Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine. Expert Rev Anti Infect Ther 2007, 5:717-726.
141. Rassi A Challenges and opportunities for primary secondary, and tertiary prevention of Chagas disease. Heart 2009, 95:524-534.
142. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009, 7:157-163.
143. Molina J, Martins-Filho O, Brener Z, et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000, 44:150-155.
144. Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 2003, 21:27-38.
145. Garzoni LR, Caldera A, Mde N Meirelles, et al. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int J Antimicrob Agents 2004, 23:273-285.
146. Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. PLoS Negl Trop Dis 2009, 3:e488.
147. Escribà JM, Ponce E, Ade D Romero, et al. Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras. Mem Inst Oswaldo Cruz 2009, 104:986-991.
148. Priotto G, Kasparian S, Ngouama D, et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 2007, 45:1435-1442.
149. Ferraz ML, Gazzinelli RT, Alves RO, Urbina JA, Romanha AJ The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother 2007, 51:1359-1364.
150. Yamagata Y, Nakagawa J Control of chagas disease. Adv Parasitol 2006, 61:129-165.
151. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gürtler RE The challenges of Chagas Disease-grim outlook or glimmer of hope. PLoS Med 2007, 4:e332.
152. Miles MA, Feliciangeli MD, de Arias AR American trypanosomiasis (Chagas' disease) anf the role of molecular epidemiology in guiding control strategies. BMJ 2003, 326:1444-1448.
153. Schofield CJ, Kabayo JP Trypanosomiasis vector control in Africa and Latin America. Parasit Vectors 2008, 1:24.
154. Wilson LS, Strosberg AM, Barrio K Cost-effectiveness of Chagas disease interventions in Latin America and the Caribbean: Markov models. Am J Trop Med Hyg 2005, 73:901-910.